272 Capital LP Takes Position in Certara, Inc. (NASDAQ:CERT)

272 Capital LP purchased a new position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 50,000 shares of the company's stock, valued at approximately $586,000.

Several other hedge funds have also recently modified their holdings of the stock. Blue Trust Inc. acquired a new stake in Certara during the 2nd quarter worth about $26,000. Innealta Capital LLC purchased a new position in shares of Certara in the second quarter worth about $36,000. KBC Group NV lifted its holdings in shares of Certara by 48.2% during the third quarter. KBC Group NV now owns 4,873 shares of the company's stock worth $57,000 after purchasing an additional 1,584 shares during the period. Intech Investment Management LLC purchased a new stake in Certara in the second quarter valued at approximately $152,000. Finally, Algert Global LLC acquired a new position in Certara in the 2nd quarter worth approximately $156,000. Institutional investors and hedge funds own 73.96% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on CERT shares. Barclays decreased their price objective on shares of Certara from $14.00 to $12.00 and set an "equal weight" rating for the company in a research note on Thursday, November 7th. UBS Group upgraded shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 target price for the company in a research report on Friday, September 27th. Finally, Robert W. Baird lowered their price target on shares of Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a report on Tuesday, November 5th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, Certara presently has an average rating of "Hold" and a consensus price target of $15.92.

Insider Activity

In related news, insider Patrick F. Smith sold 5,409 shares of the company's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the transaction, the insider now owns 50,091 shares in the company, valued at $552,503.73. This represents a 9.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.39% of the company's stock.

Certara Stock Performance

NASDAQ CERT traded down $0.24 during mid-day trading on Friday, reaching $11.47. 1,828,639 shares of the stock were exchanged, compared to its average volume of 837,594. Certara, Inc. has a 1 year low of $9.41 and a 1 year high of $19.87. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The business's 50 day moving average is $10.84 and its 200-day moving average is $12.70. The company has a market capitalization of $1.85 billion, a P/E ratio of -57.05, a P/E/G ratio of 5.86 and a beta of 1.53.

Certara (NASDAQ:CERT - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. During the same period in the prior year, the company posted $0.06 EPS. The company's revenue for the quarter was up 10.7% on a year-over-year basis. On average, equities research analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.